Danippon Sumitomo Deal With BioSeek Could Be Model For Other Japanese Pharmas – BIO-Asia
This article was originally published in PharmAsia News
Executive Summary
TOKYO - BioSeek's deal last week with Danippon Sumitomo Pharma could be a model for additional deals between the Burlington, Calif.-based platform company and Japanese pharmas looking to de-risk preclinical decisions, according to BioSeek VP-Technology & Alliances Ivan Plavec